We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Vericel Corporation (VCEL - Free Report) closed at $51.15, marking a -0.04% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq lost 0.58%.
Heading into today, shares of the company had gained 29.92% over the past month, outpacing the Medical sector's gain of 1.31% and the S&P 500's gain of 4.45% in that time.
VCEL will be looking to display strength as it nears its next earnings release, which is expected to be February 24, 2021. The company is expected to report EPS of $0.21, up 5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $45.17 million, up 14.66% from the year-ago period.
It is also important to note the recent changes to analyst estimates for VCEL. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.32% higher within the past month. VCEL is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note VCEL's current valuation metrics, including its Forward P/E ratio of 132.21. This represents a premium compared to its industry's average Forward P/E of 28.04.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 202, putting it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vericel Corporation (VCEL) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Vericel Corporation (VCEL - Free Report) closed at $51.15, marking a -0.04% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq lost 0.58%.
Heading into today, shares of the company had gained 29.92% over the past month, outpacing the Medical sector's gain of 1.31% and the S&P 500's gain of 4.45% in that time.
VCEL will be looking to display strength as it nears its next earnings release, which is expected to be February 24, 2021. The company is expected to report EPS of $0.21, up 5% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $45.17 million, up 14.66% from the year-ago period.
It is also important to note the recent changes to analyst estimates for VCEL. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.32% higher within the past month. VCEL is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note VCEL's current valuation metrics, including its Forward P/E ratio of 132.21. This represents a premium compared to its industry's average Forward P/E of 28.04.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 202, putting it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.